A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma

• J. Kaczmar,
• K. Papadopoulos,
• G. Ansstas,
• A. Birnbaum,
• J. Mehnert,
• O. Hamid,
• B. Hughes,
• G. Rabinowits,
• A. Wei,
• M. Yushak,
• J. Mani,
• F. Fang,
• J. Wang,
• G. Kroog,
• M. Salvati,
• I. Lowy,
• M. Fury,
• N.J. Lakhani

Affiliations

J. Kaczmar

MUSC Hollings Cancer Center, North Charleston, United States of America

K. Papadopoulos

START, San Antonio, United States of America

G. Ansstas

Washington University School of Medicine, St. Louis, United States of America

A. Birnbaum

Rhode Island Hospital, Providence, United States of America

J. Mehnert

Rutgers Cancer Institute of New Jersey, New Brunswick, United States of America

O. Hamid

The Angeles Clinical and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, United States of America

B. Hughes

Royal Brisbane and Women's Hospital and University of Queensland, Brisbane, Australia

G. Rabinowits

Miami Cancer Institute, Miami, United States of America

A. Wei

Columbia University, New York, United States of America

M. Yushak

Department of Hematology and Medical Oncology at Emory University School of Medicine, Atlanta, United States of America

J. Mani

Regeneron Pharmaceuticals, Inc., Tarrytown, United States of America

F. Fang

Regeneron Pharmaceuticals, Inc., Tarrytown, United States of America

J. Wang

Regeneron Pharmaceuticals, Inc., Tarrytown, United States of America

G. Kroog

Regeneron Pharmaceuticals, Inc., Tarrytown, United States of America

M. Salvati

Regeneron Pharmaceuticals, Inc., Tarrytown, United States of America

I. Lowy

Regeneron Pharmaceuticals, Inc., Tarrytown, United States of America

M. Fury

Regeneron Pharmaceuticals, Inc., Tarrytown, United States of America

N.J. Lakhani

START Midwest, Grand Rapids, United States of America